Genetic analysis of attenuation markers of cold-adapted X-31 influenza live vaccine donor strain

Yo Han Jang; Eun Ju Jung; Kwang Hee Lee; Young Ho Byun; Seung Won Yang; Baik Lin Seong

doi:10.1016/j.vaccine.2016.01.053

Genetic analysis of attenuation markers of cold-adapted X-31 influenza live vaccine donor strain

Yo Han Jang, Eun Ju Jung, Kwang Hee Lee, Young Ho Byun, Seung Won Yang, Baik Lin Seong

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Cold-adapted live attenuated influenza vaccines (CAIVs) have been considered as a safe prophylactic measure to prevent influenza virus infections. The safety of a CAIV depends largely on genetic markers that confer specific attenuation phenotypes. Previous studies with other CAIVs reported that polymerase genes were primarily responsible for the attenuation. Here, we analyzed the genetic mutations and their phenotypic contribution in the X-31 ca strain, a recently developed alternative CAIV donor strain. During the cold-adaptation of its parental X-31 virus, various numbers of sequence changes were accumulated in all six internal genes. Phenotypic analysis with single-gene and multiple-gene reassortant viruses suggests that NP gene makes the largest contribution to the cold-adapted (ca) and temperature-sensitive (ts) characters, while the remaining other internal genes also impart attenuation characters with varying degrees. A balanced contribution of all internal genes to the attenuation suggests that X-31 ca could serve as an ideal master donor strain for CAIVs preventing influenza epidemics and pandemics.

Original language	English
Pages (from-to)	1343-1349
Number of pages	7
Journal	Vaccine
Volume	34
Issue number	11
DOIs	https://doi.org/10.1016/j.vaccine.2016.01.053
Publication status	Published - 2016 Mar 8

Bibliographical note

Funding Information:
This research was supported by the Vaccine Translational Research Center funded by the Ministry of Health and Welfare of Korean government (Grant No. HI13C0826 ) and also by the National Research Foundation of Korea (NRF) (Grant Nos. NRF2015R1D1A4A01016640 and NRF2014M3A9E4064743 ). The funding source did not have roles in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

All Science Journal Classification (ASJC) codes

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2016.01.053

Fingerprint Dive into the research topics of 'Genetic analysis of attenuation markers of cold-adapted X-31 influenza live vaccine donor strain'. Together they form a unique fingerprint.

Cite this

@article{2c02d62729db432b896b2cf01d4e279f,

title = "Genetic analysis of attenuation markers of cold-adapted X-31 influenza live vaccine donor strain",

abstract = "Cold-adapted live attenuated influenza vaccines (CAIVs) have been considered as a safe prophylactic measure to prevent influenza virus infections. The safety of a CAIV depends largely on genetic markers that confer specific attenuation phenotypes. Previous studies with other CAIVs reported that polymerase genes were primarily responsible for the attenuation. Here, we analyzed the genetic mutations and their phenotypic contribution in the X-31 ca strain, a recently developed alternative CAIV donor strain. During the cold-adaptation of its parental X-31 virus, various numbers of sequence changes were accumulated in all six internal genes. Phenotypic analysis with single-gene and multiple-gene reassortant viruses suggests that NP gene makes the largest contribution to the cold-adapted (ca) and temperature-sensitive (ts) characters, while the remaining other internal genes also impart attenuation characters with varying degrees. A balanced contribution of all internal genes to the attenuation suggests that X-31 ca could serve as an ideal master donor strain for CAIVs preventing influenza epidemics and pandemics.",

author = "Jang, {Yo Han} and Jung, {Eun Ju} and Lee, {Kwang Hee} and Byun, {Young Ho} and Yang, {Seung Won} and Seong, {Baik Lin}",

note = "Funding Information: This research was supported by the Vaccine Translational Research Center funded by the Ministry of Health and Welfare of Korean government (Grant No. HI13C0826 ) and also by the National Research Foundation of Korea (NRF) (Grant Nos. NRF2015R1D1A4A01016640 and NRF2014M3A9E4064743 ). The funding source did not have roles in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. ",

year = "2016",

month = mar,

day = "8",

doi = "10.1016/j.vaccine.2016.01.053",

language = "English",

volume = "34",

pages = "1343--1349",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "11",

}

TY - JOUR

T1 - Genetic analysis of attenuation markers of cold-adapted X-31 influenza live vaccine donor strain

AU - Jang, Yo Han

AU - Jung, Eun Ju

AU - Lee, Kwang Hee

AU - Byun, Young Ho

AU - Yang, Seung Won

AU - Seong, Baik Lin

N1 - Funding Information: This research was supported by the Vaccine Translational Research Center funded by the Ministry of Health and Welfare of Korean government (Grant No. HI13C0826 ) and also by the National Research Foundation of Korea (NRF) (Grant Nos. NRF2015R1D1A4A01016640 and NRF2014M3A9E4064743 ). The funding source did not have roles in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

PY - 2016/3/8

Y1 - 2016/3/8

N2 - Cold-adapted live attenuated influenza vaccines (CAIVs) have been considered as a safe prophylactic measure to prevent influenza virus infections. The safety of a CAIV depends largely on genetic markers that confer specific attenuation phenotypes. Previous studies with other CAIVs reported that polymerase genes were primarily responsible for the attenuation. Here, we analyzed the genetic mutations and their phenotypic contribution in the X-31 ca strain, a recently developed alternative CAIV donor strain. During the cold-adaptation of its parental X-31 virus, various numbers of sequence changes were accumulated in all six internal genes. Phenotypic analysis with single-gene and multiple-gene reassortant viruses suggests that NP gene makes the largest contribution to the cold-adapted (ca) and temperature-sensitive (ts) characters, while the remaining other internal genes also impart attenuation characters with varying degrees. A balanced contribution of all internal genes to the attenuation suggests that X-31 ca could serve as an ideal master donor strain for CAIVs preventing influenza epidemics and pandemics.

AB - Cold-adapted live attenuated influenza vaccines (CAIVs) have been considered as a safe prophylactic measure to prevent influenza virus infections. The safety of a CAIV depends largely on genetic markers that confer specific attenuation phenotypes. Previous studies with other CAIVs reported that polymerase genes were primarily responsible for the attenuation. Here, we analyzed the genetic mutations and their phenotypic contribution in the X-31 ca strain, a recently developed alternative CAIV donor strain. During the cold-adaptation of its parental X-31 virus, various numbers of sequence changes were accumulated in all six internal genes. Phenotypic analysis with single-gene and multiple-gene reassortant viruses suggests that NP gene makes the largest contribution to the cold-adapted (ca) and temperature-sensitive (ts) characters, while the remaining other internal genes also impart attenuation characters with varying degrees. A balanced contribution of all internal genes to the attenuation suggests that X-31 ca could serve as an ideal master donor strain for CAIVs preventing influenza epidemics and pandemics.

UR - http://www.scopus.com/inward/record.url?scp=84959150699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959150699&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2016.01.053

DO - 10.1016/j.vaccine.2016.01.053

M3 - Article

C2 - 26851733

AN - SCOPUS:84959150699

VL - 34

SP - 1343

EP - 1349

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 11

ER -